EPH57 The Market Dynamics of GP IIb/IIIa Inhibitors in Germany: A Closer Look at Eptifibatide and Aggrastat

GP IIb/IIIa inhibitors are widely used antiplatelet drugs used in patients with acute coronary syndrome, undergoing percutaneous coronary intervention (PCI). Prior to 2015, these inhibitors held significant market value, as they were available only in branded forms. However, during the period under review, the patent for eptifibatide and aggrastat expired, leading to the entry of generic versions with a price collapse. This research serves to observe the effects of the price changes and the reduction of sales and marketing efforts.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research